ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Jun 15, 2021||ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells|
|Jun 09, 2021||ENDRA Life Sciences Set to Join the Russell Microcap(R) Index|
|May 17, 2021||ENDRA Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update|
|May 06, 2021||ENDRA Life Sciences to Report First Quarter 2021 Financial Results on May 17, 2021|
|May 04, 2021||ENDRA Life Sciences Further Strengthens TAEUS(R) System's Intellectual Property Protection with Issuance of Two U.S. Patents|
|Day Range||2.08 - 2.20|
|52 Week Range||0.65 - 3.10|
|Bid/Ask||2.11 / 2.13|
|Bid/Ask Size||300 X 400|
|Market Cap||87.93 million|
|Shares Outstanding||41.67 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|